Modality
ERT
MOA
DLL3 ADC
Target
RET
Pathway
Epigenetic
OCDAsthma
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
Oct 2018
→ Mar 2028
Phase 1Current
NCT03866575
1,207 pts·OCD
2018-10→2028-03·Not yet recruiting
1,207 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-272.0y awayInterim· OCD
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Not yet…
Catalysts
Interim
2028-03-27 · 2.0y away
OCD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03866575 | Phase 1 | OCD | Not yet recr... | 1207 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |